• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    June 13, 2022 - FDA Approves First Systemic Treatment for Alopecia Areata

    6/13/22 3:04:15 PM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $LLY alert in real time by email
    For Immediate Release:
    June 13, 2022

    Today, the U.S. Food and Drug Administration approved Olumiant (baricitinib) oral tablets to treat adult patients with severe alopecia areata, a disorder that often appears as patchy baldness and affects more than 300,000 people in the U.S. each year. Today’s action marks the first FDA approval of a systemic treatment (i.e. treats the entire body rather than a specific location) for alopecia areata.

    “Access to safe and effective treatment options is crucial for the significant number of Americans affected by severe alopecia,” said Kendall Marcus, M.D., director of the Division of Dermatology and Dentistry in the FDA’s Center for Drug Evaluation and Research. “Today’s approval will help fulfill a significant unmet need for patients with severe alopecia areata.”

    Alopecia areata, commonly referred to as just alopecia, is an autoimmune disorder in which the body attacks its own hair follicles, causing hair to fall out, often in clumps. Olumiant is a Janus kinase (JAK) inhibitor which blocks the activity of one or more of a specific family of enzymes, interfering with the pathway that leads to inflammation.

    The efficacy and safety of Olumiant in alopecia areata was studied in two randomized, double-blind, placebo-controlled trials (Trial AA-1 and Trial AA-2) with patients who had at least 50% scalp hair loss as measured by the Severity of Alopecia Tool for more than six months. Patients in these trials received either a placebo, 2 milligrams of Olumiant, or 4 milligrams of Olumiant every day. The primary measurement of efficacy for both trials was the proportion of patients who achieved at least 80% scalp hair coverage at week 36.

    In Trial AA-1, 22% of the 184 patients who received 2 milligrams of Olumiant and 35% of the 281 patients who received 4 milligrams of Olumiant achieved adequate scalp hair coverage, compared to 5% of the 189 patients who received a placebo. In Trial AA-2, 17% of the 156 patients who received 2 milligrams of Olumiant and 32% of the 234 patients who received 4 milligrams of Olumiant achieved adequate scalp hair coverage, compared to 3% of the 156 patients who received a placebo.  

    The most common side effects associated with Olumiant include: upper respiratory tract infections, headache, acne, high cholesterol (hyperlipidemia), increase of an enzyme called creatinine phosphokinase,  urinary tract infection,  liver enzyme elevations, inflammation of hair follicles (folliculitis), fatigue, lower respiratory tract infections, nausea, genital yeast infections (Candida infections), anemia, low number of certain types of white blood cells (neutropenia), abdominal pain, shingles (herpes zoster) and weight increase.  

    Olumiant is not recommended for use in combination with other JAK inhibitors, biologic immunomodulators, cyclosporine or other potent immunosuppressants. Olumiant comes with warnings and precautions including recommending close monitoring for the development of signs and symptoms of infection during and after treatment; evaluating patients for active tuberculosis infection and testing for latent tuberculosis prior to treatment with Olumiant; and the potential for viral reactivation. In addition, other warnings and precautions include hypersensitivity (allergic reactions), gastrointestinal perforations (tears in stomach or intestine), and laboratory abnormalities including low white and red blood cell counts, liver enzyme elevations and lipid elevations.

    Olumiant comes with a boxed warning for serious infections, mortality, malignancy, major adverse cardiovascular events and thrombosis.

    Olumiant received priority review and breakthrough therapy designations for this indication.

    Olumiant was originally approved in 2018. It is approved as a treatment for certain adult patients with moderately to severely active rheumatoid arthritis. Olumiant is also approved for the treatment of COVID-19 in certain hospitalized adults.  

    The FDA granted the approval of Olumiant to Eli Lilly and Company. 
     

    Related Information

    Related Information
    • NIH: Alopecia Areata

    ###

    Boilerplate

    The FDA, an agency within the U.S. Department of Health and Human Services, protects the public health by assuring the safety, effectiveness, and security of human and veterinary drugs, vaccines and other biological products for human use, and medical devices. The agency also is responsible for the safety and security of our nation’s food supply, cosmetics, dietary supplements, products that give off electronic radiation, and for regulating tobacco products.


    Inquiries

    Media:
    Chanapa Tantibanchachai
    202-384-2219
    Consumer:
    888-INFO-FDA

    Get the next $LLY alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $LLY

    DatePrice TargetRatingAnalyst
    6/5/2025Buy → Hold
    Erste Group
    4/28/2025$1150.00 → $700.00Buy → Reduce
    HSBC Securities
    4/22/2025$975.00Overweight
    Cantor Fitzgerald
    12/10/2024$997.00Buy
    BofA Securities
    11/15/2024$1000.00Outperform
    Wolfe Research
    10/17/2024$1100.00Outperform
    Bernstein
    9/13/2024$1060.00Buy
    Citigroup
    8/12/2024$1025.00Hold → Buy
    Deutsche Bank
    More analyst ratings

    $LLY
    SEC Filings

    See more
    • SEC Form 11-K filed by Eli Lilly and Company

      11-K - ELI LILLY & Co (0000059478) (Filer)

      6/20/25 4:23:15 PM ET
      $LLY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SD filed by Eli Lilly and Company

      SD - ELI LILLY & Co (0000059478) (Filer)

      5/9/25 4:12:45 PM ET
      $LLY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Eli Lilly and Company filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

      8-K - ELI LILLY & Co (0000059478) (Filer)

      5/8/25 4:34:55 PM ET
      $LLY
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $LLY
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Eli Lilly downgraded by Erste Group

      Erste Group downgraded Eli Lilly from Buy to Hold

      6/5/25 7:52:21 AM ET
      $LLY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Eli Lilly downgraded by HSBC Securities with a new price target

      HSBC Securities downgraded Eli Lilly from Buy to Reduce and set a new price target of $700.00 from $1,150.00 previously

      4/28/25 8:33:23 AM ET
      $LLY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cantor Fitzgerald initiated coverage on Eli Lilly with a new price target

      Cantor Fitzgerald initiated coverage of Eli Lilly with a rating of Overweight and set a new price target of $975.00

      4/22/25 7:32:42 AM ET
      $LLY
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $LLY
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Eli Lilly and Company

      SC 13G/A - ELI LILLY & Co (0000059478) (Subject)

      10/23/24 5:17:34 PM ET
      $LLY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Eli Lilly and Company (Amendment)

      SC 13G/A - ELI LILLY & Co (0000059478) (Subject)

      2/13/24 5:04:42 PM ET
      $LLY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Eli Lilly and Company (Amendment)

      SC 13G/A - ELI LILLY & Co (0000059478) (Subject)

      1/26/24 4:25:45 PM ET
      $LLY
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $LLY
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Sulzberger Gabrielle was granted 6 shares, increasing direct ownership by 0.24% to 2,580 units (SEC Form 4)

      4 - ELI LILLY & Co (0000059478) (Issuer)

      6/17/25 6:28:26 PM ET
      $LLY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Luciano Juan R was granted 18 shares, increasing direct ownership by 0.11% to 16,362 units (SEC Form 4)

      4 - ELI LILLY & Co (0000059478) (Issuer)

      6/17/25 6:26:05 PM ET
      $LLY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Hedley Mary Lynne was granted 12 shares, increasing direct ownership by 0.63% to 1,960 units (SEC Form 4)

      4 - ELI LILLY & Co (0000059478) (Issuer)

      6/17/25 6:23:14 PM ET
      $LLY
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $LLY
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • New AI Rollouts Signal Shift From Hype to Healthcare Reality

      USA News Group News CommentaryIssued on behalf of Avant Technologies Inc. VANCOUVER, BC, June 24, 2025 /PRNewswire/ -- With populations again, and chronic diseases on the rise, global healthcare systems are facing enormous challenges ahead. However, there is hope on the horizon to alleviate some of these burdens, coming from the rise of AI in healthcare, as the new tech is proving it can improve diagnostic accuracies, drug discoveries, and administration work flow. Healthcare leaders are already reporting benefits, including reduced clinician workloads through voice-based AI tools and the use of AI agents to boost efficiency and support smarter care delivery. Behind the scenes, the tech is b

      6/24/25 9:45:00 AM ET
      $LLY
      $PHG
      $PLTR
      $WAY
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Medical Electronics
      Computer Software: Prepackaged Software
    • Lilly declares third-quarter 2025 dividend

      INDIANAPOLIS, June 23, 2025 /PRNewswire/ -- The board of directors of Eli Lilly and Company (NYSE:LLY) has declared a dividend for the third quarter of 2025 of $1.50 per share on outstanding common stock. The dividend is payable on September 10, 2025, to shareholders of record at the close of business on August 15, 2025. About LillyLilly is a medicine company turning science into healing to make life better for people around the world. We've been pioneering life-changing discoveries for nearly 150 years, and today our medicines help tens of millions of people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new dis

      6/23/25 11:37:00 AM ET
      $LLY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Lilly's once-weekly insulin efsitora alfa demonstrated A1C reduction and a safety profile consistent with daily insulin in multiple Phase 3 trials

      Results from the fixed-dose QWINT-1 study, along with the QWINT-3 and QWINT-4 studies, reinforce efsitora's potential to simplify insulin management with weekly dosing Lilly plans to submit efsitora for the treatment of adults with type 2 diabetes to global regulatory agencies by the end of this year INDIANAPOLIS, June 22, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) today announced detailed results from QWINT-1, QWINT-3, and QWINT-4 Phase 3 clinical trials evaluating the safety and efficacy of investigational once-weekly insulin efsitora alfa (efsitora) in adults with type 2 diabetes who used insulin for the first time, previously used daily basal insulin, and previously used daily

      6/22/25 2:31:00 PM ET
      $LLY
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $LLY
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • May 31, 2024 - FDA Roundup: May 31, 2024

      For Immediate Release: May 31, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, the FDA approved mRESVIA (Respiratory Syncytial Virus Vaccine) for the prevention of lower respiratory tract disease (LRTD) caused by respiratory syncytial virus (RSV) in individuals 60 years of age and older. mRESVIA is an mRNA-based vaccine that is manufa

      5/31/24 3:22:42 PM ET
      $LLY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • May 7, 2024 - FDA Roundup: May 7, 2024

      For Immediate Release: May 07, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, the FDA announced a meeting of the Psychopharmacologic Drugs Advisory Committee on June 4 to discuss a new drug application for midomafetamine (MDMA) capsules, submitted by Lykos Therapeutics, for the treatment of post-traumatic stress disorder. The committ

      5/7/24 4:10:24 PM ET
      $LLY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • December 5, 2023 - FDA Roundup: December 5, 2023

      For Immediate Release: December 05, 2023 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, registration opened for the FDA’s virtual Rare Disease Day on Friday, March 1, 2024. This year’s Rare Disease Day is dedicated to patients and health care professionals. Panels will discuss efforts to address the unique challenges with developing treat

      12/5/23 5:00:21 PM ET
      $LLY
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $LLY
    Leadership Updates

    Live Leadership Updates

    See more
    • New AI Rollouts Signal Shift From Hype to Healthcare Reality

      USA News Group News CommentaryIssued on behalf of Avant Technologies Inc. VANCOUVER, BC, June 24, 2025 /PRNewswire/ -- With populations again, and chronic diseases on the rise, global healthcare systems are facing enormous challenges ahead. However, there is hope on the horizon to alleviate some of these burdens, coming from the rise of AI in healthcare, as the new tech is proving it can improve diagnostic accuracies, drug discoveries, and administration work flow. Healthcare leaders are already reporting benefits, including reduced clinician workloads through voice-based AI tools and the use of AI agents to boost efficiency and support smarter care delivery. Behind the scenes, the tech is b

      6/24/25 9:45:00 AM ET
      $LLY
      $PHG
      $PLTR
      $WAY
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Medical Electronics
      Computer Software: Prepackaged Software
    • Asha Therapeutics Awarded Barnett Drug Development Grant by the ALS Association to Advance Novel Intra-Molecular Glue Inhibitor of SARM1 to Clinic and Announces Appointment of Disarm Therapeutics' Founders to Company's Scientific Advisory Board

      Asha Therapeutics (Asha), a life sciences company pioneering breakthrough therapeutics for neurological disease, announced today the company has been awarded a grant from the ALS Association through its Lawrence and Isabel Barnett Drug Development Program for the advancement of ASHA-624, a novel brain-penetrant intra-molecular glue inhibitor of SARM1. The grant will support the continued development of ASHA-624 towards first-in-human clinical trials as a potential disease-modifying therapeutic for Amyotrophic Lateral Sclerosis (ALS). ASHA-624 was designed using Asha's proprietary PRISM™ drug design technology, which creates new medicines to restore normal biology and provide functional cu

      11/13/24 9:30:00 AM ET
      $LLY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Lilly appoints Lucas Montarce as executive vice president and chief financial officer

      INDIANAPOLIS, Sept. 9, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced the appointment of Lucas Montarce as executive vice president and chief financial officer (CFO) and member of the company's Executive Committee, effective immediately. Since joining Lilly in 2001, Montarce has held a range of finance leadership roles, including serving as group vice president, corporate controller and chief financial officer of Lilly Research Laboratories; vice president, finance and chief financial officer of Lilly International; and vice president, finance and global chief financial officer of Elanco Health. He most recently served in the role of Lilly president and general manage

      9/9/24 6:45:00 AM ET
      $LLY
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $LLY
    Financials

    Live finance-specific insights

    See more
    • Lilly declares third-quarter 2025 dividend

      INDIANAPOLIS, June 23, 2025 /PRNewswire/ -- The board of directors of Eli Lilly and Company (NYSE:LLY) has declared a dividend for the third quarter of 2025 of $1.50 per share on outstanding common stock. The dividend is payable on September 10, 2025, to shareholders of record at the close of business on August 15, 2025. About LillyLilly is a medicine company turning science into healing to make life better for people around the world. We've been pioneering life-changing discoveries for nearly 150 years, and today our medicines help tens of millions of people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new dis

      6/23/25 11:37:00 AM ET
      $LLY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Lilly declares second-quarter 2025 dividend

      INDIANAPOLIS, May 5, 2025 /PRNewswire/ -- The board of directors of Eli Lilly and Company (NYSE:LLY) has declared a dividend for the second quarter of 2025 of $1.50 per share on outstanding common stock. The dividend is payable on June 10, 2025, to shareholders of record at the close of business on May 16, 2025. About LillyLilly is a medicine company turning science into healing to make life better for people around the world. We've been pioneering life-changing discoveries for nearly 150 years, and today our medicines help tens of millions of people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discoveries

      5/5/25 12:47:00 PM ET
      $LLY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Lilly reports first-quarter 2025 financial results and highlights pipeline momentum

      Revenue in Q1 2025 increased 45% to $12.73 billion driven by volume growth from Mounjaro and Zepbound. Pipeline progress included positive Phase 3 trial results for orforglipron (small molecule oral GLP-1 agonist) in Type 2 diabetes in the first of seven obesity and diabetes Phase 3 trials.Q1 2025 EPS increased 23% to $3.06 on a reported basis and increased 29% to $3.34 on a non-GAAP basis, both inclusive of $1.72 of acquired IPR&D charges.Revenue guidance reaffirmed to be between $58.0 billion and $61.0 billion. INDIANAPOLIS, May 1, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced its financial results for the first-quarter of 2025. "Lilly had a solid start to the year

      5/1/25 6:45:00 AM ET
      $LLY
      Biotechnology: Pharmaceutical Preparations
      Health Care